

REMARKS

Status of Claims

Claim 1 has been amended.

Claims 12-14 and 22-29 have been canceled.

Claims 1-11, 15-21, and 30-31 are allowed.

Allowable Subject Matter

Applicants note with appreciation that Claims 1-11, 15-21, and 30-31 are allowed.

Amendments to the Claims:

Applicants have amended Claim 1 to exclude R⁶ = C₁-galkyl from the scope of Claim 1.

No new matter is added by the way of this amendment.

In order to expedite prosecution of the present application, Applicants have canceled Claims 12-14 and 22 to exclude the non-elected subject matter. Cancellation of 12-14 and 22 does not constitute any admission regarding this subject matter. Applicants reserve a right to pursue this subject matter in this or other application(s).

Conclusion

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: April 5, 2006

Galina Yakovleva

Galina M. Yakovleva, Ph.D.
Attorney For Applicants
Registration No. 47,192

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-6095
Fax: (858) 678-8233